The Max Planck Institute of Psychiatry is a scientific institute based in the city of Munich in Germany specializing in psychiatry. Currently directed by Elisabeth Binder and Alon Chen, it is one of the 81 institutes in the Max Planck Society.

During the past decade, Max Planck Institute of Psychiatry conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 1 clinical trials were completed, i.e. on average, 16.7% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Max Planck Institute of Psychiatry" #1 sponsor was "Max-Planck-Institute of Psychiatry" with 9 trials, followed by "Ludwig-Maximilians - University of Munich" with 2 trials sponsored, "Affectis Pharmaceuticals AG" with 1 trials sponsored, "Charite University, Berlin, Germany" with 1 trials sponsored and "Chiasma, Inc." with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Max Planck Institute of Psychiatry" #1 collaborator was "Dr. Kade/Besins Pharma GmbH, Rigistr. 2, 12277 Berlin" with 1 trials as a collaborator, "FGK Clinical Research GmbH" with 1 trials as a collaborator, "German Research Foundation" with 1 trials as a collaborator, "Ludwig-Maximilians - University of Munich" with 1 trials as a collaborator and "Max-Planck-Institute of Psychiatry" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Max Planck Institute of Psychiatry" are "Major Depression" (3 trials), "Depressive Disorder" (2 trials), "Healthy" (2 trials), "Major Depressive Disorder" (2 trials) and "Schizophrenia" (2 trials). Many other conditions were trialed in "Max Planck Institute of Psychiatry" in a lesser frequency.

Most popular intervention types in "Max Planck Institute of Psychiatry" are "Drug" (8 trials), "Behavioral" (3 trials), "Other" (2 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Venlafaxine" (2 trials), "15 minute counseling interview" (1 trials), "Amitriptyline" (1 trials) and "Amitriptylinoxide" (1 trials). Other intervention names were less common.

The vast majority of trials in "Max Planck Institute of Psychiatry" are 13 trials for "All" genders, 1 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Max Planck Institute of Psychiatry". undefined are not yet recruiting, 2 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in Max Planck Institute of Psychiatry, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Max Planck Institute of Psychiatry, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 7 trials that are defined as “Not Applicable".